Clinical Value of Folate-Receptor Positive Circulating Tumor Cell in Diagnosing Papillary Thyroid Cancer: A Retrospective Study

Author:

Liang Liu1,Ye Wei1,Rao Hui1,Guo Xuemin1

Affiliation:

1. Meizhou People's Hospital

Abstract

Abstract Backgrounds: Folate receptor-positive circulating tumor cells (FR+CTCs) have been proven effective in cancer diagnosis; this study aims to investigate the clinical significance of FR+CTC in diagnosing papillary thyroid cancer (PTC) patients. Methods: This retrospective study enrolled 1129 patients. Ligand-targeted polymerase chain reaction (LT-PCR) was utilized to detect FR+CTC. Variables with statistical significance were selected to draw the ROC curves, and accordingly, sensitivity, specificity, and AUC were calculated for comparison. The clinical data were used to construct univariate and multivariate logistic regression models. A predicting model was established, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Results: 846 patients were finally included, of which 433 were clustered into the benign group and 413 were categorized into the papillary thyroid cancer (PTC) group. There were significant differences between FR+CTC, TSH, TT3, FT3, Tg, TgAb, and Age of the two groups (P<0.05). The AUCs of the above seven risk factors were 0.690 (95% CI, 0.654-0.725), 0.632 (95% CI, 0.594-0.669), 0.567 (95% CI, 0.528-0.606), 0.585 (95% CI, 0.547-0.623), 0.735 (95% CI, 0.701-0.769), 0.588 (95% CI, 0.549-0.626) and 0.646 (95% CI, 0.609-0.683), respectively. The AUC of the combined model was 0.815 (95% CI, 0.785-0.844). The univariate and multivariate analysis identified age (OR, 0.41; 95% CI: 0.29-0.57), FR+CTC (OR, 3.7; 95% CI: 2.65–5.22), TSH (OR, 3.18; 95% CI: 2.22-4.59) and Tg (OR, 0.25; 95% CI: 0.18-0.35) as independent predictors. Conclusions: FR+CTCs is a potential biomarker to distinguish PTC and is correlated with tumor location, ATA risk stratification (between high risk and low risk group), and N stage. Trial registration: Not applicable.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3